Genmab

MA strategy deal block push come together form
Biotech

Genmab pays $8B to buy Merus and phase 3 bispecific

Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.
James Waldron Sep 29, 2025 5:38am
RD oil pipeline

Genmab discards ADC from $1.8B ProfoundBio buy

Sep 16, 2025 10:33am
parachutes sky italy sun blue

Pfizer’s reputation wrangler plans departure—Chutes & Ladders

Jul 11, 2025 8:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Endometrial cancer data on Genmab's Elahere rival beat forecast

May 23, 2025 9:22am
Manila folder with CONFIDENTIAL printed on it in red

AbbVie alleges Genmab 'willfully blind' to trade secret theft

Mar 24, 2025 5:51am
concept of growth and then decline

Genmab axes anti-CD38 antibody after losing J&J support

Mar 10, 2025 2:13pm